About 63% achieved at least 5% weight loss, and 33% lost 10% or more
What Customers Feel After 30 Days Average rating 4.8/5 from 61,000+ verified buyers
In the original 2017 mouse study, FOXO4-DRI was reported as well-tolerated in vivo at the dosing used
This created challenges for patients who needed it to manage diabetes
STEER was a retrospective, observational real-world study, evaluating the efficacy of Wegovy (semaglutide 2.4 mg) versus tirzepatide for the prevention of MACE in US adults with overweight or obesity and established CVD with no prior history of diabetes, with a primary outcome measure of revised 5-point MACE (heart attack, stroke, hospitalisation for heart failure, coronary revascularisation, and death from any cause) and revised 3-point MACE (heart attack, stroke and death from any cause)
Yet, amidst the chatter, it's not uncommon to find a haze of confusion